Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals' stock experienced volatility over the past six months. In August 2025, the company reported increased net losses but raised $10.6 million through public offerings. October 2025 saw stock surges driven by light news and speculation. In November 2025, the stock showed bullish momentum. December 2025 included a 1-for-25 reverse stock split and a stock surge due to positive clinical updates from a breast cancer study for NGC-Cap, leading to an increased price target. January 2026 saw restricted stock unit vesting and positive preliminary data. In February 2026, the stock moved upwards. Overall, the stock has experienced a significant decline over the past year despite some positive movement.

As a clinical-stage biopharmaceutical company, Processa Pharmaceuticals does not have direct demand seasonality for its products. However, stock price data suggests potential seasonality, with May having the highest probability of a positive return and January the lowest, likely reflecting investor sentiment rather than product demand.

Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company focused on developing Next Generation Chemotherapy (NGC) oncology drug products. The company uses a regulatory science approach to advance its pipeline of small-molecule oncology drugs, modifying already FDA-approved cancer drugs to improve safety and efficacy. Its pipeline includes PCS6422 (NGC-Cap) for metastatic colorectal and breast cancer, PCS3117 (NGC-Gemcitabine), PCS11T (NGC-Irinotecan) for various cancers, PCS499 for Ulcerative Necrobiosis Lipoidica (NL), and PCS12852 for gastroparesis and GI motility.

Processa Pharmaceuticals, Inc. is headquartered in Vero Beach, Florida, with a primary operational and market focus within the U.S., developing drug products for patients with unmet medical needs.

Processa Pharmaceuticals' brand reputation has been mixed, influenced by stock price declines and corporate actions, alongside positive clinical developments. The stock's decline and reverse stock split may negatively impact investor confidence. Positive clinical trial results, such as those for NGC-Cap, contribute positively to its scientific and medical reputation. The company's mission to develop effective pharmacological solutions also supports a positive brand image.

Processa Pharmaceuticals, Inc. has notable institutional and individual ownership. Institutional shareholders own approximately 78.60% of the company, with major holders including Stonepine Capital Management, LLC and Geode Capital Management, Llc. Significant individual owners include James E. Besser and Justin W. Yorke.